Mariner, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Mariner, LLC

$55.8 Billion
Q3 2024

A detailed history of Mariner, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Mariner, LLC holds 11,728 shares of REGN stock, worth $8.38 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

11,728

Previous 10,829 8.3%

Holding current value

$8.38 Million

Previous $11.4 Million 8.32%

% of portfolio

0.02%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1024.09 - $1201.76 $920,656 - $1.08 Million	899 Added 8.3%	11,728 $12.3 Million
Q2 2024 Aug 13, 2024	SELL	$883.2 - $1071.19 $113,932 - $138,183	-129 Reduced 1.18%	10,829 $11.4 Million
Q1 2024 May 15, 2024	BUY	$902.69 - $993.35 $335,800 - $369,526	372 Added 3.51%	10,958 $10.5 Million
Q4 2023 Feb 14, 2024	BUY	$775.18 - $881.7 $2.38 Million - $2.71 Million	3,068 Added 40.81%	10,586 $9.3 Million
Q3 2023 Nov 13, 2023	BUY	$692.45 - $844.37 $148,184 - $180,695	214 Added 2.93%	7,518 $6.19 Million
Q2 2023 Aug 11, 2023	BUY	$700.03 - $830.35 $154,006 - $182,677	220 Added 3.11%	7,304 $5.25 Million
Q1 2023 May 12, 2023	BUY	$680.49 - $826.97 $574,333 - $697,962	844 Added 13.53%	7,084 $5.82 Million
Q4 2022 Feb 14, 2023	BUY	$705.89 - $766.39 $229,414 - $249,076	325 Added 5.49%	6,240 $4.5 Million
Q3 2022 Nov 10, 2022	BUY	$573.97 - $724.32 $3.4 Million - $4.28 Million	5,915 New	5,915 $4.08 Million
Q2 2019 Aug 14, 2019	SELL	$299.6 - $414.82 $256,757 - $355,500	-857 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$372.08 - $439.57 $49,858 - $58,902	134 Added 18.53%	857 $352,000
Q4 2018 Feb 13, 2019	BUY	$335.82 - $403.04 $242,797 - $291,397	723 New	723 $270,000

Others Institutions Holding REGN

# of Institutions

1,534

Shares Held

83.6M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $76.6B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.

Account